The production and secretion of antibodies by human plasma cells (PCs) are two essential processes of humoral immunity. The secretion process relies on a group of proteins known as soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), which are located in the plasma membrane (t-SNAREs) and in the antibody-carrying vesicle membrane (v-SNARE), and mediate the fusion of both membranes. We have previously shown that SNAP23 and STX4 are the t-SNAREs responsible for antibody secretion. Here, using human PCs and antibody-secreting cell lines, we studied and characterized the expression and subcellular distribution of vesicle associated membrane protein (VAMP) isoforms, demonstrating that all isoforms (with the exception of VAMP1) are expressed by the referenced cells. Furthermore, the functional role in antibody secretion of each expressed VAMP isoform was tested using siRNA. Our results show that VAMP2 may be the v-SNARE involved in vesicular antibody release. To further support this conclusion, we used tetanus toxin light chain to cleave VAMP2, conducted experiments to verify co-localization of VAMP2 in antibody-carrying vesicles, and demonstrated the coimmunoprecipitation of VAMP2 with STX4 and SNAP23 and the in situ interaction of VAMP2 with STX4. Taken together, these findings implicate VAMP2 as the main VAMP isoform functionally involved in antibody secretion.
INTRODUCTION
After B-lymphocytes are exposed to antigen, these cells differentiate into the final stage of the B-cell lineage commitment, the plasma cells (PCs), which are known as the key effector elements of the humoral immune response. PCs are regarded as specialized cells with the exclusive function of synthesizing and secreting immunoglobulins (Igs), 1 although this assumption has recently been challenged. 2, 3 PCs have a high secretory capacity of up to several thousand antibody molecules per second. 4 Therefore, they require extensive development of the secretory pathway cellular structures, including the endoplasmic reticulum (ER), the polyribosomes and secretory vesicles, and accordingly, they exhibit an increased cytoplasmic-to-nuclear ratio compared with the B-cell progenitors. 5 Igs are confined to small carrier vesicles before secretion 6 and are constitutively secreted from the cell into the extracellular space through the classical secretory pathway. 7 The cell membrane fusion and, particularly, the fusion between secretory vesicles and the plasma membrane for exocytosis must be specific to maintain organelle identity, cell function and viability, and it requires a molecular mechanism to juxtapose and fuse the two membranes involved. This process is performed by a set of proteins called SNAREs (soluble N-ethyl-maleimide sensitive factor attachment protein receptors). 8, 9 SNARE proteins were initially classified as v-SNAREs and t-SNAREs according to their presence on either vesicle membranes or on the corresponding target membranes, respectively. SNAREs also mediate homotypic membrane fusion, for example, the fusion of two similar vesicles, and these proteins have more recently been classified as R-SNAREs and Q-SNAREs according to the central amino acid contained in the zero layer. 10 The v-SNAREs include proteins of the Synaptobrevin family (also called vesicle associated membrane proteins (VAMPs), from the vesicle-associated membrane proteins), and the t-SNAREs include proteins of the Syntaxin and SNAP-25 families. In general, syntaxins and VAMPs associate with the membrane via one transmembrane domain (TMD), 8, 11 whereas SNAP-25 proteins are associated with membranes via several palmitate chains. 12 There are numerous isoforms of t-SNARE (Syntaxins and SNAP-25) and v-SNARE (VAMPs), 9, 13 and the specific interactions among them could partially determine the different membrane compartments that are allowed to fuse within the cells. 14 The SNARE proteins assemble into a core complex composed of a parallel four-helical coiled-coil bundle in which one helix belongs to one Syntaxin protein, another helix belongs to one VAMP protein and another two helices belong to one SNAP-25 protein. The interactions between SNARE proteins initially begin between their cytoplasmic N-terminal domains and proceed to the membrane-anchored C-terminal domains, bringing the opposing membranes sufficiently close enough to facilitate fusion. 15 Toxins have been used to investigate the roles of SNAREs in cells. Many SNARE proteins are proteolytic substrates of clostridial neurotoxins. Tetanus toxin and botulinum toxin are examples of such toxins, and the cleavage of SNARE proteins results in the inhibition of exocytosis; however, not all SNARE isoforms are susceptible to these toxins. 16 It has been hypothesized that Ig secretion from PCs is mediated by constant trafficking of vesicles containing Igs to the cell surface. On their arrival, the Igs are discharged by exocytosis without further storage. 17 As final mediators of the humoral immune response, secreted soluble antibodies usually serve to protect the individual against infection. However, some antibodies and the immune complexes formed by them are also directly or indirectly implicated in the pathology of autoimmune diseases, 18 atopic disease 19 or gammopathy-associated renal diseases. 20 Despite the importance of Ig secretion in disorders such as these, little research has been published on the SNARE proteins involved in this process.
In previous studies, SNAP23 has been identified and characterized as the SNAP-25 family member, and STX, as the syntaxin family member involved in Ig secretion by human PCs; [21] [22] [23] however, the VAMP family member, that is, the other component necessary to form the SNARE complex, remains to be identified. The aim of the present study was, therefore, to analyze which isoform/s of the VAMP protein/s is/are implicated in Ig secretion by human PCs. Here, we describe the various VAMP isoforms expressed by human PCs and antibodysecreting cell lines detected by western blotting. In addition, we use immunofluorescence (IF) microscopy to elucidate the subcellular distribution of each VAMP isoform and used other integrated strategies, such as VAMP expression knockdown by small interfering RNA (siRNA), VAMP treatment with tetanus toxin and dominant-negative assays, to demonstrate that VAMP2 is involved in the secretion of Ig by human PCs.
MATERIALS AND METHODS

Antibodies
The following antibodies against human proteins were purchased from the following suppliers: rabbit polyclonal anti-VAMP1 (Synaptic Systems, Göttingen, Germany), mouse monoclonal anti-VAMP2 (R&D systems, Minneapolis, MN, USA), rabbit polyclonal anti-VAMP2 (Abcam, Cambridge, UK), rabbit polyclonal anti-VAMP3 (Abcam), anti-VAMP4 and anti-VAMP8 rabbit polyclonal antibodies (Synaptic Systems), rabbit polyclonal anti-VAMP5 (Biorbyt, Cambridge, UK and Sigma-Aldrich, Madrid, Spain), mouse monoclonal anti-VAMP7 (Covalab, Cambridge, UK), goat anti-HA HRP (Horseradish peroxidase)-conjugated (GenScript, Piscataway, NJ, USA) and mouse monoclonal anti-β-actin (Abcam). HRP-conjugated secondary antibodies were purchased from Sigma-Aldrich (Madrid, Spain). For IF microscopy, rabbit anti-VAMP2 (Abcam), FITC-conjugated anti-human IgE (Biosource, Camarillo, CA, USA), primary anti-human catalase, RAB9, LAMP1, EEA1 antibodies (Cell Signaling Technologies, Danvers, MA, USA) and Alexa-647 or Alexa-488 secondary anti-mouse or antirabbit antibodies (Invitrogen, Madrid, Spain) were used. For ELISA, alkaline phosphatase-conjugated and unconjugated antibody pairs against human IgE were obtained from Biosource. For the immunodot blots and for IF of plated vesicles, the selected primary antibodies were mouse anti-VAMP2 (Abcam) and goat anti-human IgG, IgM, and IgA (H+L) (Life Technologies, Carlsbad, CA, USA), and the secondary antibodies were anti-mouse Alexa-680 (Life Technologies), rabbit anti-goat Dylight 800 (Rockland, Gilbertsville, PA, USA) and goat antimouse Alexa-488 and goat anti-rabbit tertiary antibody Alexa-568 (Life Technologies).
Tissue samples and cell lines
The human cell lines U266 and IM9 were purchased from the European Collection of Cell Cultures (ECACC, Salisbury, UK), and the RPMI-1788 cell line was purchased from the Coriell Institute for Medical Research Biorepository (Camden, NJ, USA). U266 and IM9 were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 . The same culture conditions, excluding the glutamine addition, were used for the RPMI-1788 cell line.
Multiple myeloma PC (MMPC) was purified from donated bone marrow aspirate of diagnosed MM patients using monoclonal anti-CD138-coated microbeads (Miltenyi-Biotec, Auburn, CA, USA). Human tonsil PC (To-PC) was obtained and purified as previously described. 24 All human samples were obtained from adult donors with written informed consent under the supervision and approval of the Institutional Review Board (Ethics Committee for Research at the Hospital Universitario Puerta del Mar, Cadiz, Spain).
Western blotting
Cells were washed twice with PBS buffer and centrifuged, and the cell pellets were re-suspended in lysis buffer (125 mM TrisHCl, 2% SDS, 1 mM DTT, pH 6.8) containing a protease inhibitor cocktail (Sigma, Madrid, Spain). Following sonication, the protein concentration was quantified using a micro-BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Proteins (20 μg) were resolved by 15% SDS-PAGE and transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA). Total protein lysates from human brain, serving as a control, were obtained from Biochain (Newark, CA, USA). Membranes were blocked with 5% skim milk in buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% Tween-20) and incubated with the appropriate primary antibody overnight a 4°C. After three washes with TBS-Tween, the membranes were incubated with HRP-conjugated secondary antibody for 1 h at rom temperature (RT) and then washed three more times with TBS-Tween. Bound antibodies were detected using the Immuno Star Western C kit with a ChemiDoc XRS system (Bio-Rad, Madrid, Spain). The blots were then re-probed with β-actin antibody as a loading control. Bands were quantified using the Quantity One Bio-Rad program, and the signal ratio was calculated for VAMP/β-actin.
Preparation of vesicles
The cell lysate supernatant was centrifuged for 30 min at 45 000g. The pellet was scraped off, homogenized in 40 mM sucrose and then added to a sucrose gradient (200-400 mM). After spinning for 2 h at 57 000g, a central band containing the vesicles was removed with a syringe. This fraction was aliquoted and then stored at − 80°C until use.
Immunodot blot
Immunodot blots were performed on PVDF membranes to detect VAMP2 and/or IgM. Briefly, 1 μl of vesicle samples were applied directly to PVDF membranes and then thoroughly dried and rinsed with methanol and PBS. Following a 1-h blocking step with Odyssey blocking buffer, product number 927-40100 (LI-COR, Lincoln, NE, USA), a mouse anti-VAMP2 or a goat anti-human IgM was added, diluted in the same blocking buffer, and then incubated overnight at 4°C. The membranes were then washed three times with PBS-triton X-100 (1%), and then once more with PBS. The membranes were then incubated with rabbit anti-goat Dylight 800 or goat anti-mouse Alexa fluor-680 for 1 h. Finally, after a washing cycle as indicated above, the membranes were visualized using an Odyssey Infrared Imaging System (LI-COR).
IF microscopy U266 cells were incubated on poly-lysine treated slides for 1 h at 37°C. They were then fixed in 4% (w/v) paraformaldehyde in PBS for 15 min at 4°C, washed three times with PBS and then permeabilized with 0.1% Triton X-100 in PBS. After washing three times with PBS, the cells were incubated in blocking solution (5% normal FBS in PBS) for 1 h at RT to block nonspecific antibody binding. The cells were then incubated with the appropriate primary antibody in blocking solution for 2 h. After washing three times with PBS, the cells were incubated with the appropriate fluorescence-conjugated secondary antibody for 1 h at RT in the dark. After three more washes with PBS, the protein localization in the cells was analyzed using a laser confocal TCS-SL microscope system from Leica Microsystems (Barcelona, Spain). Regarding vesicle IF, vesicle fraction samples from RPMI-1788 cells were diluted 1:10 in PBS and centrifuged for 30 min at 29 000g. The pellets were then diluted 1:1 using either dH 2 0 (hypo-osmotic samples) or PBS (isoosmotic samples). Approximately 40 μl of each sample was added to poly-d-lysine-coated coverslips and blocked with non-fat-milk for 30 min. Either mouse anti-human VAMP2 (Abcam) and/or goat anti-human IgG, IgM, and IgA (H+L) (Life Technologies) were added and allowed to incubate for 2 h at 4°C. The antibody mixture was then removed, and the plates were rinsed twice with PBS. Subsequently, a secondary antibody, rabbit anti-goat Dylight 800 (Life Technologies), was added and, after three washing steps, a secondary goat anti-mouse Alexa Fluor488 and a tertiary antibody, Alexa-568 goat anti-rabbit (Life Technologies), were also added. In the controls, antibodies were added to the dishes, but they were not plated with vesicles. The images were analyzed by fluorescence microscopy, and the corresponding images were taken with a Canon Power Shot A650 IS camera (Canon Inc., Melville, NY, USA).
Coimmunoprecipitation (Co-IP) assays U266 cells were solubilized in lysis buffer (50 mM Tris-HCl pH 7,4, 150 mM NaCl, 2 mM EDTA, 1% (w/v) NP-40, 0,1% SDS supplemented with protease inhibitor cocktail from Sigma) for 1 h at 4°C in a rotating wheel. Following centrifugation at 12 000g for 10 min at 4°C, the clarified supernatants were collected as total cell lysates. The samples were then immunoprecipitated overnight at 4°C, together with a pre-incubated antibody attached to the anti-VAMP2-Dynabeads protein G (Life Technologies) or an isotype mouse serum-protein G as a negative control. The beads were subsequently collected with a magnetic stand, washed three times with lysis buffer and eluted with SDS-PAGE sample buffer. Thereafter, the referenced samples were boiled and subjected to western blotting (WB) analysis with the STX4, SNAP23 and VAMP2 antibodies.
siRNA silencing assays For siRNA knockdown experiments using the U266 cell line, siRNA On-TARGET plus SMART pool (Dharmacon, Lafayatte, CO, USA) references L-012498-00 for VAMP2, L-011934-00 for VAMP3, L-004241-00 for VAMP4, L-017684-00 for VAMP5, L-020864-00 for VAMP7 and L-013503-00 for VAMP8, were used to inhibit VAMP production, whereas D-001600-01 as siGLO RISC-free siRNA served as a negative control. Cells (2 × 10 6 ) were transfected by nucleofection with Amaxa Nucleofector II (Lonza, Barcelona, Spain) using 100 nM siRNA for each condition and the program (X-005) recommended by the manufacturer. For all cases, the nucleofected cells were cultured for 48 h. After refreshing the culture media and normalizing the number of cells for each particular condition, the cells were cultured for an additional 24 h, and the cell pellets and supernatants were collected and analyzed as stated for each experiment.
Constructs and expression of fusion proteins cDNA for producing full-length human wild-type VAMP2 (wtVAMP2) and transmembrane domain deleted VAMP2 (VAMP2-ΔTMD) proteins was generated by PCR from U266 using oligonucleotide primers as follows (small letters indicate cloning sites, capital letters specific cDNA coding VAMP2); 5′-cgatatcgtcgacaccATGTCGGCTACCGCTGCCAC-3′ as sense primer for both cDNAs, and 5′-ggatcctttaccggtGAGCTGAAG TAAACTATG-3′ and 5′-ggatcctttaccggtTTGAGGTTTTTCCA CCAG-3′ as antisense primer for wtVAMP2 and VAMP2-ΔTMD, respectively. The cDNAs were cloned in-frame to the amino-terminus of the monomeric red fluorescent Ruby protein 25 and verified by DNA sequence analysis. The cDNA of the tetanus toxin light chain (TeNT-LC) (a kind gift from Professor G. Schiavo, Institute of Neurology, University College London) was amplified by PCR and sub-cloned into the pIRES2-EGFP expression vector. U266 cells were transfected with 2 μg of DNA plasmid for all constructs stated in the experiment according to the manufacturer's instructions using an Amaxa nucleofector. At 48 h after transfection, fluorescent cells were isolated by fluorescence-activated cell sorting (FACS) and then cultured for an additional 24 h. The cell pellets and supernatants were then analyzed by microscopy, western blotting and ELISA.
Flow cytometry and FACS
Transfection efficiencies were usually analyzed 48 h after electroporation using a BD Biosciences FACSCalibur flow cytometer. Data were analyzed using Cell Quest software (BD Biosciences, Madrid, Spain). When isolation of transfected cells was required, a FACSAria sorter (BD Biosciences) was used. For the intracellular IgE flow cytometry analysis, post-transfected cells with the corresponding constructs were stained with anti-human IgE-FITC (Life Technologies) using the fixation and permeabilization IntraStain kit (Dako, Glostrup, Denmark) according to the manufacturer's instruction. Transfected cells (Ruby positive cells), were analyzed using a FACSCalibur flow cytometer, and the mean fluorescence intensity (MFI) for intracellular IgE-FITC staining was determined.
ELISA
Suspensions of siRNA-transfected cells or plasmid-transfected FACS-sorted cells were cultured in a 24-well plate using 5 × 10 5 cells per well or in a 96-well plate using 1 × 10 5 cells per well, respectively. After 24 h, cell-free supernatants were collected, and the level of IgE secretion was evaluated by sandwich ELISA in microtiter plates as previously reported. 26 For quantifications of intracellular IgE, after the cell pellets were previously lysed in buffer (50 mM Tris-HCl pH = 8, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, protease inhibitors), ELISA were performed as described above.
Statistical analysis
The results are generally expressed as the mean and SEM. Data were analyzed using the Mann-Whitney U test to determine significant differences between any two experimental groups, except for Figure 3 , in which the ANOVA test and Tukey post-hoc test were applied. P values o0.05 were considered significant.
RESULTS
Expression and cellular localization of VAMP proteins in human antibody-secreting cells
To determine, which of the seven VAMP protein members were expressed in human PCs, samples of normal primary PCs from tonsil, PCs from MM patients, and two different antibodysecreting cell lines, U266 and IM9, were studied using WB and IF techniques. The expression of VAMP1 was absent in all PCs tested (Figure 1) . However, the other members, VAMP2, − 3, − 4, − 5, − 7 and − 8, were detected, although differences in the level of expression were observed among the tested PCs (Figure 1) . Quantifications of the bands observed in Figure 1 and quantifications of the bands from other U266 WB experiments (total n = 4) are included as Supplementary Table S1 . As expected, VAMP2 and VAMP3 were detected at higher levels in human brain extracts compared with VAMP4, VAMP5, VAMP7 and VAMP8, which were expressed at very low levels (Figure 1 , lane C). The most apparent differences among human Igsecreting cells were detected for the IM9 cell line, which showed reduced VAMP3 expression, and for the U266 cell line, which exhibited high VAMP7 expression compared with the other PC samples (Figure 1 ). Other significant reductions in expression were observed for VAMP5 in MMPC samples. VAMP2, VAMP4 and VAMP8 displayed more uniform expression. All bands detected in the PC samples had the same sizes as in the brain samples, excluding VAMP5, which presented two bands in IM9 cells and brain, and only one band in U266, To-PCs and MMPCs samples. Table S1 .
In general, a cytoplasmic vesicular localization, associated with the exocytic and/or the endocytic pathway, has been described for VAMPs. However, the intracellular distribution of the VAMP isoforms has been shown to differ between different cell types (for review ref. 13 ). Therefore, using IF techniques, we studied the cellular distribution of the VAMP isoforms expressed in the U266 and IM9 cell lines and in MMPC from patients (Figure 2) . The IF results showed that VAMP2, VAMP3, VAMP4 and VAMP8 presented a punctuated staining pattern predominantly in the cytoplasm, indicating a vesicular localization. VAMP5 and VAMP7 also presented cytoplasmic staining, although it was more intense, patched and perinuclearly localized. These results were similar in all cells tested and suggest that all VAMPs might function as potential v-SNAREs in the fusion of the antibodycarrying vesicles with the plasma membrane.
Effects of VAMP protein reduction by siRNA on antibody secretion To provide functional evidence for which VAMP proteins might be implicated in the antibody secretion process, we next examined the role played by each in this process by downregulating each VAMP isoform using RNAi approaches. To knockdown VAMPs, U266 cells were nucleofected with specific siRNA, and the antibody secretion level was determined 3 days after nucleofection. As shown in Figure 3a , efficient knockdown after siRNA treatment resulted in a significant reduction in the levels of each VAMP proteins compared with cells treated with a negative siRNA control. The degree of each VAMP knockdown ranged between 50 and 90% compared with the control treated cells. However, only the reduction of VAMP2 by siRNA (Figure 3b) had a statistically significant effect on antibody secretion into the cultured medium. In contrast, siRNAmediated knockdown of the other VAMP proteins did not show any significant effect. Because siRNA previously demonstrated a reduction in Ig secretion, 22 a specific siRNA for STX4 was used as a positive control. The combination of two VAMP siRNA simultaneously, that is, for VAMP2+VAMP3 or VAMP7 +VAMP8, revealed no differences compared with the single siRNA (not shown). A similar phenomena, that is, no functionally significant effect after SNARE knockdown, has been previously described and attributed to a functional compensation and/or protein redundancy. 27 However, our data suggested that VAMP2 might be implicated in the secretion of antibody by human PCs. Co-localization of Ig-carrying vesicles and VAMP2 protein To verify that Igs were contained in cytoplasmic membrane vesicles, cultures of RPMI-1788 cells, an IgM-secreting cell line, were used. The presence of IgM in the supernatant and inside of the vesicle were tested in cell fraction by sucrose gradient techniques and dot-blot assays. Both supernatants and the cell vesicle-containing fraction were positive for IgM detection ( Figure 4A ). Moreover, the vesicle fraction samples were spread onto poly-d-lysine coverslips and examined for the presence of IgM by indirect IF, as indicated by Figure 4B . IF images were positive only when the vesicle fractions were lysed, showing that the Igs were contained in the lumen of the membrane vesicles. To determine whether Ig-containing vesicles also contained VAMP2, purified vesicle fractions from RPMI-1788 cells were laid onto poly-lysine-coated coverslips and then tested for colabeling of IgM and VAMP2. As seen in Figure 4C , panels a-c, IF images displayed positive labeling for IgM or for VAMP2 antibodies compared with the negative control without primary antibodies. When both primary antibodies were added together ( Figure 4C panels d,e) , co-localization was observed in the overlay image (panel f), indicating that the IgM-containing vesicles also contained VAMP2 in their membranes. An analysis of colocalization showed a Pearson's correlation coefficient of R = 0.9324 for signals obtained in panels d,e. This result was also corroborated using IF microscopy, detecting a partial colocalization, when U266 cells were examined simultaneously for IgE and VAMP2 ( Figure 5 , upper panels). To assess whether VAMP2 was restricted to antibody-containing vesicles, a double labeling assay was performed, combining the anti-VAMP2 antibody with antibodies directed to the lysosome marker LAMP1, the early endosome marker EEA1, the late endosome marker RAB9 and the peroxisome maker catalase. The results revealed no co-localization ( Figure 5, merged panels) . Considering these data together, we concluded that both Igs and VAMP2 Figure 3 Effects of gene silencing of vesicle associated membrane proteins (VAMPs) on the secretion of IgE by PCs. U266 cells were transiently nucleofected with 100 μM siRNA against each VAMP isoform and small interfering RNA (siRNA) controls as described in 'Material and methods' section. Two days after transfection, an equal number of cells (5 × 10 5 ) for each condition were placed in a 24-well plate, cultured for 24 h and then the pellet and the supernatant were collected and analyzed by WB and ELISA, respectively. (a) The efficiency of VAMP knockdown was determined using assays examining the cell pellets by WB followed by specific band quantification. The numbers under the bands indicate the mean ± s.e.m. (n = 4) of the remaining protein compared with the control siRNA used. (b) Quantification of IgE secretion from U266 cells. The IgE content in the supernatants from cultured VAMP siRNA-silenced cells after transfection with targeting siRNA or siControl was measured by ELISA. The relative level of IgE secretion for each targeting siRNA was compared with the non-targeting siRNA control. The number of independent experiments performed for each condition was n = 12 for siControl and VAMP2, n = 5 for VAMP5, n = 4 for STX4 and n = 9 for VAMP3, − 4, − 7 and − 8. ANOVA and the Tukey post-hoc test were applied. Data represent the mean ± s.e.m., and the asterisk denotes *Po0.05.
co-localized in vesicles, even in different cell lines producing different Ig isotypes.
Effect of TeNT-LC on Ig secretion in the U266 cell line Many of the SNARE proteins are targets for neurotoxins from Clostridium sp., and considering that VAMP2 and VAMP3 can be proteolyzed by the light chain of the Tetanus toxin (TeNT-LC), 28, 29 we decided to test whether antibody secretion could be inhibited by expressing the TeNT-LC in U266 cells. To achieve this goal, TeNT-LC cDNA was cloned in a vector with an IRES-EGFP cassette and transfected in U266 cells. The transfection efficiency was approximately 50% (green cells detected by cytometry). To avoid interference due to the other 50% non-transfected cells, only TeNT-LC-expressing green cells Osmotically unlysed (b) or lysed (c) vesicle fractions were laid on poly-lysine treated coverslips, probed with a goat anti-human IgM antibody and analyzed with a rabbit anti-goat Dyligth-800 antibody followed by a goat anti-rabbit tertiary antibody, Alexa-568, and visualized by IF microscopy. As a negative control (a), no primary antibody was added to the reaction. The results show that IgM could be only detected in the lysed vesicles. (C) Purified and lysed vesicle fractions were laid on poly-lysine coverslips and tested for co-labeling of VAMP2 and IgM. For VAMP2, (a) a mouse anti-human VAMP2 primary antibody and a goat anti-mouse Alexa Fluor488 conjugate as a secondary antibody was used. For IgM detection (b), goat anti-human IgM as a primary antibody and a rabbit anti-goat Dyligth-800 antibody as a secondary antibody followed by goat anti-rabbit Alexa-568 was used. For the negative control (c), no primary antibody was added to the reaction. For co-localization (d,e), a single coverslip preparation was incubated with both primary and secondary/tertiary antibody pairs described in a and b. An overlay image is shown (f), and arrows indicate some of the colocalizations. All images were acquired with a 10 × objective fluorescence microscope (Zeiss ISC 25).
were isolated by cell sorting, and then the effect of the toxin on the level of antibody secretion was measured by ELISA. Figure 6a shows that secretion was significantly reduced to~20%, a level similar to what previously observed using an siRNA specific for VAMP2 (Figure 3b ). TeNT-LC was fully functional and specific, as observed in Figure 6b , because both VAMP2 and VAMP3 proteins were largely, but not totally, removed, as observed in the overexposed right panel. VAMP7, as a TeNT-LC-insensitive protein, was not affected. 30 Cells transfected with the empty vector were used as a control for protein expression. β-actin was used as a loading control. The reduction observed during secretion was not due to a decrease in cell viability (Supplementary Figure S1) . To identify whether the simultaneous knockdown of several VAMPs could produce greater inhibition, we decided to test the effect of VAMP4, VAMP5, VAMP7 and VAMP8 siRNAs in previously TeNT-LCtransfected U266 cells. As controls, siRNA for STX4, an empty vector, or the TeNT-LC vector were used. Figure 6c shows the Ig secreted into the cultured media and Figure 6d , the Ig retained in the cells, both were measured by ELISA as is described in Material and Methods. The results demonstrated that for all cases, the TeNT-LC produced a reduction of Ig secretion as observed in Figure 6a , but the inhibition of IgE secretion was no further reduced when any of the siRNA of VAMPs was additionally transfected. siRNA for STX4 alone displayed the expected inhibition but did not show any increase in the inhibition of Ig secretion when it was cotransfected with the TeNT-LC. An inverse correlation of the amount of Ig retained in the cells compared with that secreted was observed (Figure 6d ).
Ig secretion is inhibited in U266 cells expressing VAMP2 lacking the TMD VAMP proteins are anchored to the vesicle membrane by their carboxyl-terminal TMD. 8 To further support the involvement of VAMP2 in the antibody secretion process and to alleviate the possible protein redundancy effect after siRNA or TeNT-LC approaches, we decided to perform a dominant-negative assay. 31, 32 Thus, we constructed a wild-type VAMP2 (wtVAMP2) and VAMP2 protein lacking the TMD (VAMP2-ΔTMD), bearing both monomer red fluorescent protein, Ruby, fused at their carboxyl-terminus. Ruby-only-expressing vector and wtVAMP2-Ruby and VAMP2-ΔTMD-Ruby-fused proteinexpressing vectors were transfected into U266 cells. Figure 7a shows that Ruby-only transfected cells, as expected, exhibited disperse fluorescence (left panel). The wtVAMP2-Ruby transfected cells gave rise to typical punctuate vesicular staining. In contrast, VAMP2-ΔTMD-Ruby-transfected cells exhibited markedly disperse and mislocalized fluorescence. The results of the IgE secretion level obtained after the expression of these constructs are shown in Figure 7b . VAMP2-ΔTMD expression provoked a significant decrease in IgE secretion compared with Ruby alone or wtVAMP2-Ruby constructs, indicating that the integrity of the VAMP2 protein is necessary to maintain normal IgE secretion by PCs, and suggesting a competition of the deleted isoform with the endogenous VAMP2 during its interaction with the other SNARE partners. Again, this reduction in IgE secretion was not due to a differential viability of the cells (Supplementary Figure S2) . If VAMP2 participates in the IgE secretion process, it is reasonable to assume that transfected cells expressing VAMP2-ΔTMD constructs must show an intracellular accumulation of IgE molecules. As shown in Figure 7c , IgE intracellular staining of transfected cells measured by the MFI was higher for VAMP2-ΔTMD cells compared with Ruby alone or wtVAMP2-Ruby constructs.
Interaction between VAMP2 and STX4 in human PCs
We next investigated whether VAMP2 could mediate Igs secretion through its interaction with SNARE proteins located at the plasma membrane. Considering that VAMP2 seems to be responsible, at least in part, for Ig secretion by PCs, it was hypothesized that it had to be complexed with other SNAREs, such as SNAP23 21 and/or STX4, 22, 23 which are equally involved in the antibody secretion process. To confirm this, we examined whether VAMP2 could interact in situ with STX4 using the proximity ligation assay technique and confocal microscopy. As shown in Figure 8a , we observed fluorescent spots in the cells when two antibodies for VAMP2, raised in different species, were used as a positive control (central panels). Only a few spots were observed when a pair of VAMP2 and STX4 antibodies was used, but they were localized in the plasma membrane (lower panels). No signal was observed in negative control samples in which one of the primary antibodies was not included (upper panels). The number of spots per cell for each condition is shown in Figure 8b . Moreover, VAMP2 and STX4 interactions were also corroborated by Co-IP experiments (Figure 8c ). VAMP2 and STX4 were separately immunoprecipitated from U266 cell lysates, and after WB, both immunoprecipitates were probed for VAMP2, STX4 and SNAP23. As a control for IP, an unspecific isotype antibody was used. As shown in Figure 8c , we found that, although not prominently, both STX4 and SNAP23 were specifically coimmunoprecipitated with VAMP2.
DISCUSSION
It has been previously reported, that Ig secretion by PCs is mediated by the two Q-SNARE proteins SNAP23 (ref. 21) and STX4. 22, 23 In the present work, we focused on the vesicleassociated R-SNARE proteins implicated in this process. 33 Initially, we noticed that PCs express all VAMP family members, except VAMP1. All the other VAMP members were expressed in all Ig-secreting cells tested, although with certain differences in their expression levels, as has been recently reported for adipocytes. 34 The different expression levels of these VAMP members do not seem to reflect a clear relationship with their possible role in Ig secretion. Thus, VAMP2, − 3, − 4 and − 8 are all regularly expressed in human PCs, but in the present work, only VAMP2 could be determined to be directly involved in Ig secretion. Notably, MMPCs presented diminished VAMP5 expression compared with the To-PCs and cell lines. Further work will be required to clarify this point. The cellular distribution of expressed VAMPs by human PCs exhibited, in general, a pattern similar to that observed in other cell systems, 35 inasmuch as a given isoform can be localized in multiple intracellular compartments in the same cell or the distribution of a particular VAMP can be different in different cell types. 13 VAMP3 has been associated with early and recycling endosomes, 36 and we observed light cytoplasmic vesicular labeling with an increased presence close to the PC nucleus. VAMP4, VAMP5 and VAMP7 also appeared mainly located next to the cellular nucleus in PCs. These findings might be in concordance with previous observations in which VAMP4 was associated with early endosomes to the trans-Golgi network [36] [37] [38] or in which VAMP7 was associated with late endosomelysosomes and the trans-Golgi network, 39 but not for VAMP5, which has been described in vesicles that mediate the transport of GLUT4 to membranes in skeletal muscle cells. 40 The subcellular localization for VAMP4, VAMP5 and VAMP7 does not indicate a possible relationship with the secretion of Igs. VAMP8 was initially associated with endosomes, 41 but it is now believed to participate in other trafficking routes that have recently been described. [42] [43] [44] VAMP8 is present in human PCs and displays a uniform dotted labeling pattern in the cytoplasm. This cytoplasmic labeling suggests that VAMP8 may play a role in the transport of vesicles containing Igs to the plasma membrane. However, our functional results did not support this possibility in antibody secretion and led us to study in detail the cellular distribution of VAMP2, which displays a vesicular pattern of distribution in the cytoplasm, in some manner, that differs from the one visualized for VAMP8.
The present study shows that in human PCs, VAMP2 is confined to Ig-carrying vesicles. In addition, no evidence supporting the localization of VAMP2 in other vesicular compartments such as early or late endosomes, lysosomes or peroxisomes, or even in organelles such as mitochondria, the Golgi apparatus or the ER, was observed (not shown).
Initially, we used siRNA assays to assess the functional role of R-SNARE proteins in Ig secretion by PCs. The specific knockdown of all VAMP proteins tested had no effect on Ig secretion by PCs except for a small reduction observed with specific siRNA for VAMP2. The possible implication of VAMP2 in Ig secretion, as suggested by this latter result, was further analyzed using two different strategies.
First, taking into account that TeNT-LC is known to proteolyze VAMP2 and VAMP3, 28, 29 its cDNA was transfected into U266 cells in which the TeNT-LC was overexpressed. The specific and almost total proteolysis of VAMP2 and VAMP3 proteins observed in our system again only produced a limited inhibition of Ig secretion, likely indicating that another VAMP member, or other proteins, could substitute for the functional role in Ig secretion when VAMP2 is removed. Furthermore, in contrast to the phenomenon observed in chromaffin cells, in which overexpression of TeNT-LC completely abolishes catecholamine secretion, an effect that could be rescued by expressing either VAMP2 or VAMP3, 45 in the present study, VAMP3 was also proteolyzed and had no effect on the inhibition of Ig secretion. However, something similar to our results has been described for GLUT4 trafficking in adipocytes, 46 for which the simultaneous knockout of VAMP2, VAMP3 and VAMP8 was necessary to interrupt GLUT4 externalization. 47 Our results suggest that VAMP2 is implicated in human PC Ig secretion and that its role can be assumed by other VAMP proteins, but not VAMP3. In agreement with this interpretation, a recent study in the same cellular system has shown that VAMP3 knockdown by siRNA did not decrease the secretion of IgE by PCs. 23 Moreover, the IM9 cell line has a high IgG secretion rate but presents a greatly diminished VAMP3 expression level Table S1 ), suggesting that this VAMP is not necessary for the secretion of Igs.
The second strategy using truncation mutants was based on the observation that the TMDs of SNARE proteins have an important role in membrane fusion. 31, 48 The dominant-negative approach obtained through expressing a soluble form of VAMP2 corroborated that this isoform was implicated in Ig secretion. These truncated mutants are known to act as selective inhibitors of exocytosis, presumably by competing with endogenous proteins in the formation of SNARE complexes. [49] [50] [51] In our case, the truncated protein could be interacting with SNAP23 and/or STX4 proteins to inhibit secretion. We were able to detect an interaction of VAMP2 with SNAP23 and STX4 in homogenate fractions of PCs using Co-IP assays, although the observed level of those complexes was unexpectedly low. In contrast, positive coimmunoprecipitated complexes containing STX4/SNAP23/VAMP2 were observed in rat parotid glands, 52 although, similarly to our results, negative associations were observed for the exocytosis of human eosinophils and neutrophils. 53 It has been proposed 53, 54 that the rapid recycling of these SNARE complexes limits the ability to detect them by immunoprecipitation. This phenomenon could also explain the observation that only few fluorescent dots were detectable in the in situ interaction studies of VAMP2 with STX4 when proximity ligation assays were used.
In summary, the possible explanations for the partial effect observed with siRNA assays might be (a) molecular redundancy, that is, the protein levels remaining after knockdown are high enough to maintain their normal functionality; 27, 55, 56 (b) functional redundancy, that is, other VAMP members can substitute for the knockdown; 47 or (c) a combination of the two previous hypotheses. However, the results obtained with TeNT-LC and with VAMP2-ΔTMD lead us to prefer the functional redundancy hypothesis, if we assume that almost all detectable VAMP2 (and VAMP3) proteins were proteolyzed, as was observed by WB. In conclusion, our results demonstrate the complexity underlying antibody secretion. Regardless of the method used, siRNA knockdown, TeNT-LC or dominantnegative experiments, all provide functional data supporting the participation of VAMP2 in Ig secretion by human PCs. In addition, these experiments suggest that VAMP2 might be replaced by other(s) family member(s) that differ from VAMP3. Understanding the mechanism underlying vesicular antibody release can provide pertinent information to facilitate our understanding and the treatment of several Ig secretion-related diseases. Discovering the key players involved in antibody release will bring us one step closer to finding ways to control improper release.
